BioSpace News Archive

InDex Pharmaceuticals Holding AB announced that 30% of patients have completed the final visit in Induction Study 1 of the phase III program CONCLUDE, which is evaluating cobitolimod as a novel treatment for patients with moderate to severe, left-sided ulcerative colitis.

Data from the ongoing Phase II open-label extension (OLE) study of evobrutinib show sustained clinical efficacy and a safety profile that remains consistent with that previously reported over five years of therapy - the longest follow-up of any Bruton’s tyrosine kinase inhibitor (BTKi) in multiple sclerosis (MS) studies Additional Phase II OLE data show significant and clinically meaningful improvements on mental health and quality of life measures in study participants with relapsing

Cytovation ASA, a clinical stage immune-oncology company focused on the development of CyPep-1, its first-in-class, dual-acting targeted tumor immunotherapy, announces positive initial data from Part 2 of its Phase 1/2a CICILIA basket trial with all trial endpoints met.

AM-Pharma B.V. announced positive clinical results from the Phase 1b study evaluating the company’s proprietary recombinant alkaline phosphatase, ilofotase alfa, as potential enzyme replacement therapy in adult hypophosphatasia patients.

BioCardia®, Inc. announces completion of enrollment in its CardiAMP Heart Failure Trial and initiation of a discussion with the FDA on a second pivotal study protocol adapted for the responders in the initial trial with the objective of gaining FDA marketing approval.

Immuron Limited, an Australian based and globally integrated biopharmaceutical company is pleased to announce record quarterly sales of its over-the-counter gastrointestinal and digestive health immune supplement Travelan®.

Faron Pharmaceuticals Ltd. announces updated data from the Phase 1/2 BEXMAB study investigating bexmarilimab in combination with standard of care in relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes patients having failed hypomethylating agents.

Axsome Therapeutics, Inc., a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders, announced that Susan Mahony, PhD, has been appointed to Axsome’s board of directors, effective immediately.

PureTech Health plc, a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, presented clinical data supporting the differentiated profile of LYT-100 at the CHEST Annual Meeting in Honolulu, Hawaii.

Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, announced the details of two poster presentations at IDWeek 2023, being held virtually and in person in Boston, MA on October 11-15.